Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284
February 24, 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ease-of-use for patients,...
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
February 22, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
ITCI submits Supplemental New Drug Applications (sNDAs) for the treatment of depressive episodes associated with bipolar I or II disorder both as monotherapy and as adjunctive therapy in adults.If...
Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 19, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast
February 17, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research
January 21, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
Patients with stable symptoms of schizophrenia were switched from previous antipsychotic medications with no dose titration to CAPLYTA 42 mg for a 6-week treatment duration, then switched back to...
Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder
December 29, 2020 08:00 ET
|
Intra-Cellular Therapies Inc.
The Company continues expansion of its lumateperone programs with the advancement of a Long-Acting injectable formulation into clinical trials. ITI-333 introduces a unique pharmacology for the...
Intra-Cellular Therapies Highlights Lumateperone Presentations at the 59th Annual Meeting of the American College of Neuropsychopharmacology
December 09, 2020 08:00 ET
|
Intra-Cellular Therapies Inc.
Presentations highlight lumateperone’s broad antidepressant effects in patients with bipolar disorder and in patients with schizophrenia with co-morbid depression NEW YORK, Dec. 09, 2020 (GLOBE...
Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx Conference
November 30, 2020 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 09, 2020 07:30 ET
|
Intra-Cellular Therapies Inc.
Positive topline results reported from Study ‘402, a Phase 3 Study evaluating lumateperone as an adjunctive treatment to lithium or valproate in patients with bipolar depression. Company is preparing...